Targeted temperature management (TTM) is usually described by its cooling phase. Yet clinicians who run TTM protocols often point to the end of the therapy as the most delicate part: bringing the patient back to normal temperature. Done too quickly, rewarming can undo much of what cooling achieved.
What TTM is and when it is used
TTM is the controlled regulation of a patient's body temperature to protect the brain and other organs from secondary injury. Its classic indication is the comatose patient after cardiac arrest with return of spontaneous circulation. When circulation stops, brain cells are deprived of oxygen; when it returns, reperfusion triggers a second wave of injury involving inflammation, excitotoxicity and oxidative stress, unfolding over hours to days. Lowering or tightly controlling temperature slows the metabolic processes that drive this damage.
Beyond cardiac arrest, temperature management is used after ischaemic stroke, in newborns with hypoxic-ischaemic encephalopathy, in febrile patients, in accidental hypothermia, during endovascular procedures and in trauma. Contraindications include coagulopathy, sepsis, haemodynamic instability, haemorrhagic stroke and uncontrolled bleeding, and every patient needs an individual assessment before therapy starts.
How the evidence changed the target
Two trials published in 2002, the Hypothermia after Cardiac Arrest (HACA) study and the Australian trial led by Bernard, both in the New England Journal of Medicine, reported better neurological outcomes with cooling to 32–34 °C. The TTM trial (Nielsen et al., 2013) then found no significant difference in mortality between 33 °C and 36 °C, and TTM2 (Dankiewicz et al., 2021) found none between 33 °C and normothermia with early treatment of fever.
The ERC–ESICM guidelines (Sandroni et al., 2022) now recommend continuous core temperature monitoring and active prevention of fever above 37.7 °C for at least 72 hours in comatose patients after cardiac arrest. The target has changed; the need for control has not.
Three phases, three different tasks
Induction brings the patient to the target temperature. The main hazard is overshoot: a method without feedback, such as ice packs, can push temperature below the intended target. Shivering usually appears in this phase and works directly against cooling.
Maintenance holds the temperature still, often for around 24 hours in adult post-arrest protocols when a hypothermic target is used. Drifts in either direction are undesirable, which is why automatic control matters here.
Rewarming returns the patient to normothermia. It is the phase most often underestimated.
What happens in the body during rewarming
Cooling slows metabolism, reduces oxygen consumption and raises vascular resistance. Rewarming reverses all of this, and if it happens too fast the body cannot keep up.
Rewarming shock. Peripheral vessels dilate before core temperature has stabilised, returning cold, acidotic blood to the central circulation. The result can be hypotension, metabolic disturbance and cardiac instability.
Electrolyte shifts. During cooling, potassium moves into cells. During rewarming it moves back out, and a fast rise in temperature can lead to dangerous hyperkalaemia. Magnesium, phosphate and calcium shift in a similar way.
Reperfusion injury. Oxygenated blood returning to previously underperfused tissue generates reactive oxygen species that damage cells.
Cerebral effects. In the brain, rapid rewarming can worsen cerebral oedema and raise intracranial pressure, the very damage that cooling was meant to limit.
Rebound acidosis. Lactate production can rise faster than the body clears it.
How slow is slow enough
Guidance from the American Heart Association and the European Resuscitation Council describes rewarming at approximately 0.15–0.25 °C per hour. In many protocols the rewarming phase is spread over 12 to 24 hours. At that rate the cardiovascular and neurological systems can adapt, and the team has time to watch electrolytes and correct them.
A rate measured in fractions of a degree per hour is practically impossible to manage by hand across a full shift. This is the strongest argument for automated, closed-loop systems: the device reads core temperature continuously and raises it in defined steps, without a nurse adjusting the setting every few minutes.
After rewarming: the phase that is easy to forget
Reaching normothermia is not the end of the therapy. Rebound hyperthermia in the hours and days after rewarming is common in post-arrest patients and is associated with worse neurological outcomes. In practice the patient stays connected to the temperature management system in normothermia mode, rather than being disconnected the moment the target is reached.
Trends shaping temperature management
From cold to controlled. Since TTM2, the emphasis has moved from deep hypothermia to precise control and fever avoidance for at least 72 hours.
Closed-loop feedback as the standard. Evidence shows that feedback-controlled surface cooling performs on a par with intravascular cooling, while surface cooling without feedback performs worse (Ramadanov et al., 2022).
One device for the whole arc. Units increasingly expect a single system to run induction, maintenance, rewarming and fever prevention, with protocols stored on the device.
Longer device time per patient. Three days of active control mean more device time per patient, and fleet planning has to follow.
Manufacturers have followed the same direction. EM-MED, a family-owned medical device company from Kraków with more than 30 years on the market, designs its TrueCool therapeutic hypothermia system to cool and warm with the same covers and to run scheduled controlled rewarming as part of a stored protocol.
The bottom line
Rewarming is not a passive end to TTM but an active, controlled continuation of it. Slow, monitored rewarming, followed by days of fever avoidance, protects the benefit that cooling was meant to deliver.
Sources
Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. New England Journal of Medicine. 2002.
Bernard SA, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. New England Journal of Medicine. 2002.
Nielsen N, et al. Targeted temperature management at 33 °C versus 36 °C after cardiac arrest. New England Journal of Medicine. 2013.
Dankiewicz J, et al. Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest. New England Journal of Medicine. 2021.
Sandroni C, Nolan JP, Andersen LW, et al. ERC-ESICM guidelines on temperature control after cardiac arrest in adults. Intensive Care Medicine. 2022.
Ramadanov N, et al. Intravascular Versus Surface Cooling in Patients Resuscitated From Cardiac Arrest: A Systematic Review and Network Meta-Analysis With Focus on Temperature Feedback. Critical Care Medicine. 2022.
Taccone FS, Picetti E, Vincent JL. High Quality Targeted Temperature Management (TTM) After Cardiac Arrest. Critical Care. 2020.
